Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
124.3 USD | -9.91% | -4.87% | +0.20% |
04-26 | Wall Street: the worst week of 2024 is followed by the best | CF |
04-26 | Morgan Stanley Adjusts DexCom's Price Target to $132 From $122 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 67% by 2026.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With an expected P/E ratio at 71.34 and 57.34 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.20% | 49.45B | B- | ||
-2.31% | 187B | C+ | ||
-3.20% | 106B | C | ||
-5.04% | 66.9B | A | ||
+17.29% | 48B | B- | ||
+4.06% | 40.84B | B+ | ||
+2.07% | 26.48B | B | ||
+2.36% | 26.25B | A- | ||
+12.96% | 24.62B | A- | ||
-1.93% | 24.52B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DXCM Stock
- Ratings DexCom, Inc.